Caleb Alexander, MD: Thoughts on the Opioid Epidemic


A pharmacoepidemiologist offers his comments on the ongoing opioid epidemic.

The ongoing opioid epidemic is a pervasive issue that healthcare providers are working to address and ultimately curb. However, solutions are not necessarily straightforward despite progress that has been made in this domain.

In a recent interview with HCPLive®, Caleb Alexander, MD, of Johns Hopkins Bloomberg School of Medicine, explained that such a crisis of this magnitude stems from complex factors. Rather than being attributed to a singular problem or issue, the epidemic has many different facets that contribute to its prevalence and severity.

“There are certainly still enormous concerns regarding the prevalence of opioid use and the risk-benefit balance of prescription opioids in many settings in which they are used,” Alexander said.

Of course, prescription medication is not only the domain of opioids that healthcare providers are worried about. He also indicated that the use of heroin and illicit fentanyl is still of considerable concern.

Nonetheless, Alexander considered the general embracing of the opioid epidemic as a concept to be a fortunate and positive step in the right direction. Furthermore, there are many efforts that have been undertaken to improve the identification and treatment of those with opioid use disorder.  

“This is an area where primary care can especially play an important role,” Alexander concluded.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.